Ten-Year Observational Study of Patients with Lung Adenocarcinoma: Clinical Outcomes, Prognostic Factors, and Five-Year Survival Rates

<b>Background/Objectives:</b> Lung carcinoma is the leading cause of cancer-related deaths globally, with lung adenocarcinoma being the most prevalent subtype. This study aims to review the clinical data and survival outcomes of patients diagnosed with lung adenocarcinoma who underwent surgical treatment. <b>Methods:</b> We retrospectively analyzed 471 patients (mean age 65.9 ± 7.81 years, range 38-86; 53.5% women) with histopathologically confirmed lung adenocarcinoma who underwent a lobectomy, bilobectomy, or pneumonectomy between May 2012 and December 2022. All patients were followed for up to five years post-surgery. Their medical histories, including previous neoplasms, comorbidities, tumor characteristics, and symptoms, were thoroughly reviewed. We calculated the overall survival rate and evaluated the impact of tumor grading and spread through air spaces (STAS) on patient outcomes. <b>Results:</b> The survival rate for the entire cohort was 76.23%. No significant survival differences emerged between G1 and G2 tumors, whereas both showed markedly better survival rates than G3 tumors. When these findings were applied to a simplified two-tier grading system (low grade vs. high grade), survival analyses showed a clear stratification of prognosis. Patients with STAS had a lower survival rate than those without STAS. <b>Conclusions:</b> Our findings indicate that a simplified grading system may improve prognostic evaluations for lung adenocarcinoma patients. Furthermore, STAS is a crucial factor affecting survival rates and should be considered in future treatment strategies. Expanding research in this area is essential to enhance treatment approaches for lung adenocarcinoma patients.